A Trial to Study BAY1753011 in Patients With Congestive Heart Failure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 482 participants.
Also called NCT03901729
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 482 participants
- Sponsor
- Registry
-
NCT03901729 -
2018-004059-18
-
- Other papers using this trial's data
- A multicentre, randomized, double-blind, active and placebo-controlled study of pecavaptan, a dual V1a/V2 vasopressin receptor antagonist, in patients with acute heart failure: The AVANTI trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Austria, Bulgaria, Greece, Hungary, Israel, Italy, Poland, Portugal, Spain
- Registry status
- Completed
Technical summary
Registry record NCT03901729. Randomized; quadruple masking; primary purpose treatment. Start 2019-05-29 (actual); primary completion 2021-04-16 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial to Study BAY1753011 in Patients With Congestive Heart Failure
- Acronym
- AVANTI
- Condition
- Heart Failure (HF)
- Intervention (Drug)
- BAY 1753011
- Intervention (Other)
- Placebo BAY 1753011
- Intervention (Drug)
- Furosemide
- Intervention (Other)
- Placebo Furosemide
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct03901729- Content hash
c4bb11ed39b3b10247768a4db338699b6c9bce3a338fefdb9809b96c00833163